Calcium Carbonate

Identification

Name
Calcium Carbonate
Accession Number
DB06724
Type
Small Molecule
Groups
Approved, Investigational
Description

Calcium carbonate is an inorganic salt used as an antacid. It is a basic compound that acts by neutralizing hydrochloric acid in gastric secretions. Subsequent increases in pH may inhibit the action of pepsin. An increase in bicarbonate ions and prostaglandins may also confer cytoprotective effects. Calcium carbonate may also be used as a nutritional supplement or to treat hypocalcemia.

Structure
Thumb
Synonyms
  • CaCO3
  • Calcium carbonate
  • Calcium carbonate (1:1)
  • Calciumcarbonat
  • Carbonate de calcium
  • Carbonato de calcio
  • Carbonic acid calcium salt (1:1)
  • Chalk
  • E 170
  • Kalziumkarbonat
  • Kohlensaurer kalk
  • Precipitated calcium carbonate
External IDs
CI 77220 / E-170(I) / INS NO.170(I) / INS-170(I) / NDI 443
Product Images
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
7 Select AntacidTablet, chewable750 mg/1Oral7 Eleven2014-09-11Not applicableUs
Alka SeltzerTablet, chewable750 mg/1OralBest Co2013-02-08Not applicableUs
Alka-Seltzer Extra Strength Heartburn ReliefChewsTablet, chewable750 mg/1OralBayer Health Care Llc.2016-09-15Not applicableUs
Alka-Seltzer Fruit ChewsTablet, chewable750 mg/1OralBayer Health Care Llc, Consumer Care2013-03-152017-12-22Us
Alka-Seltzer Heartburn ReliefChewsTablet, chewable750 mg/1OralBayer Health Care Llc.2014-03-15Not applicableUs
Alka-Seltzer Heartburn ReliefChews Cool MintTablet, chewable750 mg/1OralBayer Health Care Llc.2014-03-152017-05-31Us
Alka-Seltzer Heartburn ReliefChews StrawberryTablet, chewable750 mg/1OralBayer Health Care Llc.2014-03-152017-08-31Us
Alka-Seltzer Heartburn ReliefChews Strawberry and OrangeTablet, chewable750 mg/1OralBayer Health Care Llc.2014-03-15Not applicableUs
Alkums antacidTablet, chewable500 mg/1OralGuardian Drug Company2012-02-01Not applicableUs
AntacidTablet1000 mg/1OralTarget Corporation.2010-02-15Not applicableUs
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Acid Controller CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2013-06-052017-11-29Us
Acid Controller CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralSafeway2008-08-062017-12-22Us
Acid Controller CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2013-06-052017-11-29Us
Acid Controller Complete dual actionCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralWalgreen2008-07-30Not applicableUs
Acid Controller Complete dual actionCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralWalgreen2008-07-302018-03-29Us
Acid Reducer CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2016-01-12Not applicableUs
Acid Reducer CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralWalgreen2016-01-29Not applicableUs
Acid Reducer CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralShopko Stores Operating2016-01-06Not applicableUs
Acid Reducer CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralWalgreen2016-01-29Not applicableUs
Acid Reducer CompleteCalcium Carbonate (800 mg/1) + Famotidine (10 mg/1) + Magnesium hydroxide (165 mg/1)Tablet, chewableOralRite Aid2009-05-152018-04-01Us
Unapproved/Other Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
28tak Gum Care ToothCalcium Carbonate (36 g/120g) + Alcloxa (.12 g/120g) + Aminocaproic Acid (.12 g/120g) + Calcium phosphate, dibasic (.12 g/120g)Paste, dentifriceOralElmeditec Co.,Ltd2018-07-01Not applicableUs
Apatite ProfessionalCalcium Carbonate (36.4 g/130g)PasteDentalSungwon Pharmaceutical Co., Ltd.2013-03-14Not applicableUs
Calcium Folic Acid Plus D ChewableCalcium Carbonate (1342 mg/1) + Boron (250 ug/1) + Cholecalciferol (300 [iU]/1) + Cyanocobalamin (125 ug/1) + Folic Acid (1 mg/1) + Magnesium cation (50 mg/1) + Pyridoxine (10 mg/1)WaferOralAcella Pharmaceuticals, LLC2010-03-23Not applicableUs
Extra-Virt Plus DHACalcium Carbonate (158 mg/1) + Ascorbic acid (28 mg/1) + Biotin (250 ug/1) + Cholecalciferol (800 [iU]/1) + Doconexent (350 mg/1) + Docusate calcium (55 mg/1) + Ferrous fumarate (29 mg/1) + Folic Acid (1.25 mg/1) + Pyridoxine hydrochloride (25 mg/1) + Vitamin E (30 [iU]/1)Capsule, gelatin coatedOralVirtus Pharmaceuticals2012-12-282018-07-20Us
Folcaps Care OneCalcium Carbonate (100 mg/1) + Alpha-Linolenic Acid (50 mg/1) + Biotin (300 mg/1) + Calcium ascorbate (24 mg/1) + Calcium threonate (1 mg/1) + Cholecalciferol (800 [iU]/1) + D-alpha-Tocopherol acetate (15 [iU]/1) + Doconexent (350 mg/1) + Docusate sodium (50 mg/1) + Folic Acid (1 mg/1) + Icosapent (100 mg/1) + Iodine (150 ug/1) + Iron (27 mg/1) + Magnesium cation (50 mg/1) + Nicotinamide (10 mg/1) + Pyridoxine hydrochloride (50 mg/1) + Riboflavin (1.5 mg/1) + Zinc (5 mg/1)Capsule, gelatin coatedOralMidlothian Laboratories2009-05-012018-01-10Us
Gesticare DHACalcium Carbonate + Ascorbic acid + Cholecalciferol + Choline bitartrate + Cyanocobalamin + D-alpha-Tocopherol acetate + Doconexent + Ferrous fumarate + Folic Acid + Icosapent + Niacin + Potassium Iodide + Pyridoxine hydrochloride + Riboflavin + Thiamine mononitrate + Zinc oxideKitJazz Pharmaceuticals Commercial Corp.2008-10-01Not applicableUs
healthy mamaBE WELL ROUNDED BE WELL ROUNDEDCalcium Carbonate (200 mg/1) + Ascorbic acid (120 mg/1) + Beta carotene (4000 [iU]/1) + Biotin (30 ug/1) + Cholecalciferol (400 [iU]/1) + Copper (2 mg/1) + Ferrous bisglycinate (28 mg/1) + Folic Acid (800 ug/1) + Magnesium oxide (30 mg/1) + Methylcobalamin (8 ug/1) + Niacin (20 mg/1) + Calcium pantothenate (10 mg/1) + Pyridoxine hydrochloride (2.6 mg/1) + Riboflavin (1.7 mg/1) + Thiamine (1.8 mg/1) + Vitamin E (30 [iU]/1) + Zinc oxide (25 mg/1)Tablet, film coatedOralMATERNAL SCIENCE, LLC2013-07-09Not applicableUs
Inatal AdvanceCalcium Carbonate (200 mg/1) + Ascorbic acid (120 mg/1) + Cholecalciferol (400 [iU]/1) + Cupric oxide (2 mg/1) + Cyanocobalamin (12 ug/1) + D-alpha-Tocopherol acetate (30 [iU]/1) + Docusate sodium (50 mg/1) + Folic Acid (1 mg/1) + Iron (90 mg/1) + Magnesium oxide (30 mg/1) + Nicotinamide (20 mg/1) + Pyridoxine hydrochloride (20 mg/1) + Riboflavin (3.4 mg/1) + Thiamine mononitrate (3 mg/1) + Vitamin A (2700 [iU]/1) + Zinc oxide (25 mg/1)Tablet, coatedOralNnodum Pharmaceuticals2005-06-10Not applicableUs
Insan Bamboosalt toothpasteCalcium Carbonate (31.25 g/100g)Paste, dentifriceDentalInsan Bamboo Salt Inc2011-02-13Not applicableUs
MagneBind 400 RxCalcium Carbonate (80 mg/1) + Folic Acid (1 mg/1) + Magnesium carbonate (115 mg/1)Tablet, film coatedOralCarilion Materials Management1999-10-18Not applicableUs
Categories
UNII
H0G9379FGK
CAS number
471-34-1
Weight
Average: 100.087
Monoisotopic: 99.947335021
Chemical Formula
CCaO3
InChI Key
VTYYLEPIZMXCLO-UHFFFAOYSA-L
InChI
InChI=1S/CH2O3.Ca/c2-1(3)4;/h(H2,2,3,4);/q;+2/p-2
IUPAC Name
calcium carbonate
SMILES
[Ca++].[O-]C([O-])=O

Pharmacology

Indication

For relief of heartburn and acid indigestion. May also be used as a nutritional supplement or to treat hypocalcemia.

Associated Conditions
Associated Therapies
Pharmacodynamics

Gastric-peptic disease occurs as a result of an imbalance between protective factors, such as mucus, bicarbonate, and prostaglandin secretion, and aggressive factors, such as hydrochloric acid, pepsin, and Helicobacter pylori (H. pylori). Antacids work by restoring acid-base balance, attenuating the pepsin activity and increasing bicarbonate and prostaglandin secretion. The acid-neutralizing capacity of calcium carbonate is 58 mEq/15 ml. When used as a nutritional supplement, calcium carbonate acts by directly increasing calcium stores within the body.

Mechanism of action

Calcium carbonate is a basic inorganic salt that acts by neutralizing hydrochloric acid in gastric secretions. It also inhibits the action of pepsin by increasing the pH and via adsorption. Cytoprotective effects may occur through increases in bicarbonate ion (HCO3-) and prostaglandins. Neutralization of hydrochloric acid results in the formation of calcium chloride, carbon dioxide and water. Approximately 90% of calcium chloride is converted to insoluble calcium salts (e.g. calcium carbonate and calcium phosphate).

Absorption

Maximal absorption occurs at doses of 500 mg or less taken with food. Oral bioavailability depends on intestinal pH, the presence of food and dosage.

Volume of distribution

Calcium is rapidly distributed taken up by skeletal tissues following absorption and distribution into extracellular fluids. Bone contains 99% of the body's calcium and the remaining 1% is approximately equally distributed between intracellular and extracellular fluids.

Protein binding

Calcium acts as a co-factor to numerous enzymes.

Metabolism

None.

Route of elimination

Excreted mainly in the feces. The majority of renally filtered calcium is reabsorbed in the ascending limb of the loop of Henle and the proximal and distal convoluted tubules. Also secreted by sweat glands.

Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1alpha-Hydroxyvitamin D5The risk or severity of adverse effects can be increased when Calcium Carbonate is combined with 1alpha-Hydroxyvitamin D5.Investigational
2,5-Dimethoxy-4-ethylamphetamineCalcium Carbonate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylamphetamine which could result in a higher serum level.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineCalcium Carbonate may decrease the excretion rate of 2,5-Dimethoxy-4-ethylthioamphetamine which could result in a higher serum level.Experimental
3-Aza-2,3-Dihydrogeranyl DiphosphateCalcium Carbonate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
3,4-MethylenedioxyamphetamineCalcium Carbonate may decrease the excretion rate of 3,4-Methylenedioxyamphetamine which could result in a higher serum level.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineCalcium Carbonate may decrease the excretion rate of 4-Bromo-2,5-dimethoxyamphetamine which could result in a higher serum level.Experimental, Illicit
AcepromazineCalcium Carbonate can cause a decrease in the absorption of Acepromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AceprometazineCalcium Carbonate can cause a decrease in the absorption of Aceprometazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetaminophenCalcium Carbonate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetophenazineCalcium Carbonate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AcetyldigitoxinCalcium Carbonate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.Approved
AcetyldigoxinCalcium Carbonate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigoxin.Experimental
AgmatineThe therapeutic efficacy of Agmatine can be decreased when used in combination with Calcium Carbonate.Experimental, Investigational
AlclometasoneThe bioavailability of Alclometasone can be decreased when combined with Calcium Carbonate.Approved
AldosteroneThe bioavailability of Aldosterone can be decreased when combined with Calcium Carbonate.Experimental, Investigational
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Calcium Carbonate.Approved
AlfacalcidolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Alfacalcidol.Approved, Nutraceutical
AlimemazineCalcium Carbonate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
AllopurinolCalcium Carbonate can cause a decrease in the absorption of Allopurinol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmcinonideThe bioavailability of Amcinonide can be decreased when combined with Calcium Carbonate.Approved
AmiodaroneThe therapeutic efficacy of Amiodarone can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
AmlodipineThe therapeutic efficacy of Amlodipine can be decreased when used in combination with Calcium Carbonate.Approved
AmphetamineCalcium Carbonate may decrease the excretion rate of Amphetamine which could result in a higher serum level.Approved, Illicit, Investigational
AranidipineThe therapeutic efficacy of Aranidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
AtazanavirCalcium Carbonate can cause a decrease in the absorption of Atazanavir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
AzelnidipineThe therapeutic efficacy of Azelnidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
BarnidipineThe therapeutic efficacy of Barnidipine can be decreased when used in combination with Calcium Carbonate.Approved
Beclomethasone dipropionateThe bioavailability of Beclomethasone dipropionate can be decreased when combined with Calcium Carbonate.Approved, Investigational
BecocalcidiolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Becocalcidiol.Investigational
BenazeprilCalcium Carbonate can cause a decrease in the absorption of Benazepril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
BenazeprilatCalcium Carbonate can cause a decrease in the absorption of Benazeprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
BencyclaneThe therapeutic efficacy of Bencyclane can be decreased when used in combination with Calcium Carbonate.Experimental
BendroflumethiazideBendroflumethiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
BenidipineThe therapeutic efficacy of Benidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
BenzphetamineCalcium Carbonate may decrease the excretion rate of Benzphetamine which could result in a higher serum level.Approved, Illicit
BenzthiazideBenzthiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
BepridilThe therapeutic efficacy of Bepridil can be decreased when used in combination with Calcium Carbonate.Approved, Withdrawn
BesifloxacinCalcium Carbonate can cause a decrease in the absorption of Besifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BetamethasoneThe bioavailability of Betamethasone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
BioallethrinThe therapeutic efficacy of Bioallethrin can be decreased when used in combination with Calcium Carbonate.Approved, Experimental
BisacodylThe therapeutic efficacy of Bisacodyl can be decreased when used in combination with Calcium Carbonate.Approved
BisoxatinThe therapeutic efficacy of Bisoxatin can be decreased when used in combination with Calcium Carbonate.Approved
BL-1020Calcium Carbonate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
BosutinibCalcium Carbonate can cause a decrease in the absorption of Bosutinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BudesonideThe bioavailability of Budesonide can be decreased when combined with Calcium Carbonate.Approved
ButaperazineCalcium Carbonate can cause a decrease in the absorption of Butaperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
CalcidiolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Calcidiol.Approved, Nutraceutical
CalcipotriolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Calcipotriol.Approved
CalcitriolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Calcitriol.Approved, Nutraceutical
Calcium AcetateThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Calcium Acetate.Approved, Investigational
Calcium PhosphateCalcium Carbonate can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Calcium phosphate dihydrateCalcium Carbonate can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CaptoprilCalcium Carbonate can cause a decrease in the absorption of Captopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CarboxyamidotriazoleThe therapeutic efficacy of Carboxyamidotriazole can be decreased when used in combination with Calcium Carbonate.Investigational
CarboxymethylcelluloseThe therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
CaroverineThe therapeutic efficacy of Caroverine can be decreased when used in combination with Calcium Carbonate.Experimental
Castor oilThe therapeutic efficacy of Castor oil can be decreased when used in combination with Calcium Carbonate.Approved, Investigational, Nutraceutical, Vet Approved
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
CefpodoximeThe serum concentration of Cefpodoxime can be decreased when it is combined with Calcium Carbonate.Approved, Vet Approved
CeftriaxoneThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Ceftriaxone.Approved
CefuroximeThe serum concentration of Cefuroxime can be decreased when it is combined with Calcium Carbonate.Approved
ChloroquineCalcium Carbonate can cause a decrease in the absorption of Chloroquine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlorothiazideChlorothiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved, Vet Approved
ChlorphentermineCalcium Carbonate may decrease the excretion rate of Chlorphentermine which could result in a higher serum level.Illicit, Withdrawn
ChlorproethazineCalcium Carbonate can cause a decrease in the absorption of Chlorproethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ChlorpromazineCalcium Carbonate can cause a decrease in the absorption of Chlorpromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
ChlortetracyclineThe serum concentration of Chlortetracycline can be decreased when it is combined with Calcium Carbonate.Approved, Investigational, Vet Approved
ChlorthalidoneChlorthalidone may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
CholecalciferolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Cholecalciferol.Approved, Nutraceutical
CiclesonideThe bioavailability of Ciclesonide can be decreased when combined with Calcium Carbonate.Approved, Investigational
CilazaprilCalcium Carbonate can cause a decrease in the absorption of Cilazapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CilnidipineThe therapeutic efficacy of Cilnidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
CinnarizineThe therapeutic efficacy of Cinnarizine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
CinoxacinCalcium Carbonate can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
CiprofloxacinCalcium Carbonate can cause a decrease in the absorption of Ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
ClevidipineThe therapeutic efficacy of Clevidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
ClobetasolThe bioavailability of Clobetasol can be decreased when combined with Calcium Carbonate.Approved, Investigational
Clobetasol propionateThe bioavailability of Clobetasol propionate can be decreased when combined with Calcium Carbonate.Approved
ClobetasoneThe bioavailability of Clobetasone can be decreased when combined with Calcium Carbonate.Approved
ClocortoloneThe bioavailability of Clocortolone can be decreased when combined with Calcium Carbonate.Approved
Clodronic AcidThe serum concentration of Clodronic Acid can be decreased when it is combined with Calcium Carbonate.Approved, Investigational, Vet Approved
ClomocyclineThe serum concentration of Clomocycline can be decreased when it is combined with Calcium Carbonate.Approved
CloprednolThe bioavailability of Cloprednol can be decreased when combined with Calcium Carbonate.Experimental
CorticotropinThe bioavailability of Corticotropin can be decreased when combined with Calcium Carbonate.Approved, Investigational, Vet Approved
Cortisone acetateThe bioavailability of Cortisone acetate can be decreased when combined with Calcium Carbonate.Approved, Investigational
CortivazolThe bioavailability of Cortivazol can be decreased when combined with Calcium Carbonate.Investigational
CyamemazineCalcium Carbonate can cause a decrease in the absorption of Cyamemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CyclandelateThe therapeutic efficacy of Cyclandelate can be decreased when used in combination with Calcium Carbonate.Approved
CyclopenthiazideCyclopenthiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Experimental
CyclophosphamideCalcium Carbonate can cause a decrease in the absorption of Cyclophosphamide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
CymarinCalcium Carbonate may increase the arrhythmogenic and cardiotoxic activities of Cymarin.Experimental
CysteamineThe bioavailability of Cysteamine can be decreased when combined with Calcium Carbonate.Approved, Investigational
Dabigatran etexilateCalcium Carbonate can cause a decrease in the absorption of Dabigatran etexilate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DabrafenibCalcium Carbonate can cause a decrease in the absorption of Dabrafenib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DanthronThe therapeutic efficacy of Danthron can be decreased when used in combination with Calcium Carbonate.Approved, Investigational, Withdrawn
DarodipineThe therapeutic efficacy of Darodipine can be decreased when used in combination with Calcium Carbonate.Experimental
DasatinibCalcium Carbonate can cause a decrease in the absorption of Dasatinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
DeferiproneThe serum concentration of Deferiprone can be decreased when it is combined with Calcium Carbonate.Approved
DeflazacortThe bioavailability of Deflazacort can be decreased when combined with Calcium Carbonate.Approved, Investigational
DelaprilCalcium Carbonate can cause a decrease in the absorption of Delapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
DelavirdineCalcium Carbonate can cause a decrease in the absorption of Delavirdine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DemeclocyclineThe serum concentration of Demeclocycline can be decreased when it is combined with Calcium Carbonate.Approved
DeslanosideCalcium Carbonate may increase the arrhythmogenic and cardiotoxic activities of Deslanoside.Approved
DesonideThe bioavailability of Desonide can be decreased when combined with Calcium Carbonate.Approved, Investigational
DesoximetasoneThe bioavailability of Desoximetasone can be decreased when combined with Calcium Carbonate.Approved
DexamethasoneThe bioavailability of Dexamethasone can be decreased when combined with Calcium Carbonate.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe bioavailability of Dexamethasone isonicotinate can be decreased when combined with Calcium Carbonate.Vet Approved
DexmethylphenidateCalcium Carbonate can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
DexniguldipineThe therapeutic efficacy of Dexniguldipine can be decreased when used in combination with Calcium Carbonate.Experimental
DextroamphetamineCalcium Carbonate may decrease the excretion rate of Dextroamphetamine which could result in a higher serum level.Approved, Illicit
DexverapamilThe therapeutic efficacy of Dexverapamil can be decreased when used in combination with Calcium Carbonate.Experimental
DiethylpropionCalcium Carbonate may decrease the excretion rate of Diethylpropion which could result in a higher serum level.Approved, Illicit
DiflorasoneThe bioavailability of Diflorasone can be decreased when combined with Calcium Carbonate.Approved
DifloxacinCalcium Carbonate can cause a decrease in the absorption of Difloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
DifluocortoloneThe bioavailability of Difluocortolone can be decreased when combined with Calcium Carbonate.Approved, Investigational, Withdrawn
DifluprednateThe bioavailability of Difluprednate can be decreased when combined with Calcium Carbonate.Approved
DigitoxinCalcium Carbonate may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.Approved, Investigational
DigoxinCalcium Carbonate may increase the arrhythmogenic and cardiotoxic activities of Digoxin.Approved
DihydrotachysterolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Dihydrotachysterol.Approved
DiltiazemThe therapeutic efficacy of Diltiazem can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Dipotassium phosphateCalcium Carbonate can cause a decrease in the absorption of Dipotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
DixyrazineCalcium Carbonate can cause a decrease in the absorption of Dixyrazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
DobutamineThe therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium Carbonate.Approved
DocusateThe therapeutic efficacy of Docusate can be decreased when used in combination with Calcium Carbonate.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Calcium Carbonate.Approved
DotarizineThe therapeutic efficacy of Dotarizine can be decreased when used in combination with Calcium Carbonate.Investigational
DoxercalciferolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Doxercalciferol.Approved
DoxycyclineThe serum concentration of Doxycycline can be decreased when it is combined with Calcium Carbonate.Approved, Investigational, Vet Approved
EfonidipineThe therapeutic efficacy of Efonidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
EldecalcitolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Eldecalcitol.Investigational
ElocalcitolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Elocalcitol.Investigational
EltrombopagThe serum concentration of Eltrombopag can be decreased when it is combined with Calcium Carbonate.Approved
ElvitegravirCalcium Carbonate can cause a decrease in the absorption of Elvitegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EmopamilThe therapeutic efficacy of Emopamil can be decreased when used in combination with Calcium Carbonate.Experimental
EnalaprilCalcium Carbonate can cause a decrease in the absorption of Enalapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
EnalaprilatCalcium Carbonate can cause a decrease in the absorption of Enalaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
EnoxacinCalcium Carbonate can cause a decrease in the absorption of Enoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EperisoneThe therapeutic efficacy of Eperisone can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
EpitizideEpitizide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Experimental
ErgocalciferolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Ergocalciferol.Approved, Nutraceutical
ErlotinibCalcium Carbonate can cause a decrease in the absorption of Erlotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EstramustineCalcium Carbonate can cause a decrease in the absorption of Estramustine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Calcium Carbonate.Approved
Etidronic acidThe serum concentration of Etidronic acid can be decreased when it is combined with Calcium Carbonate.Approved
FelodipineThe therapeutic efficacy of Felodipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
FendilineThe therapeutic efficacy of Fendiline can be decreased when used in combination with Calcium Carbonate.Withdrawn
Ferric ammonium citrateCalcium Carbonate can cause a decrease in the absorption of Ferric ammonium citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CarboxymaltoseCalcium Carbonate can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric cationCalcium Carbonate can cause a decrease in the absorption of Ferric cation resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric hydroxideCalcium Carbonate can cause a decrease in the absorption of Ferric hydroxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric oxideCalcium Carbonate can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateCalcium Carbonate can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferric pyrophosphate citrateCalcium Carbonate can cause a decrease in the absorption of Ferric pyrophosphate citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Ferric subsulfateCalcium Carbonate can cause a decrease in the absorption of Ferric subsulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
Ferric sulfateCalcium Carbonate can cause a decrease in the absorption of Ferric sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous bisglycinateCalcium Carbonate can cause a decrease in the absorption of Ferrous bisglycinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous chlorideCalcium Carbonate can cause a decrease in the absorption of Ferrous chloride resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Ferrous fumarateCalcium Carbonate can cause a decrease in the absorption of Ferrous fumarate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous gluconateCalcium Carbonate can cause a decrease in the absorption of Ferrous gluconate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous succinateCalcium Carbonate can cause a decrease in the absorption of Ferrous succinate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferrous sulfateCalcium Carbonate can cause a decrease in the absorption of Ferrous sulfate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
FerumoxidesCalcium Carbonate can cause a decrease in the absorption of Ferumoxides resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxsilCalcium Carbonate can cause a decrease in the absorption of Ferumoxsil resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FerumoxytolCalcium Carbonate can cause a decrease in the absorption of Ferumoxytol resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Fish oilThe therapeutic efficacy of Fish oil can be decreased when used in combination with Calcium Carbonate.Approved, Nutraceutical
FleroxacinCalcium Carbonate can cause a decrease in the absorption of Fleroxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FlucloroloneThe bioavailability of Fluclorolone can be decreased when combined with Calcium Carbonate.Experimental
FludrocortisoneThe bioavailability of Fludrocortisone can be decreased when combined with Calcium Carbonate.Approved, Investigational
FlumequineCalcium Carbonate can cause a decrease in the absorption of Flumequine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
FlumethasoneThe bioavailability of Flumethasone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
FlunarizineThe therapeutic efficacy of Flunarizine can be decreased when used in combination with Calcium Carbonate.Approved
FlunisolideThe bioavailability of Flunisolide can be decreased when combined with Calcium Carbonate.Approved, Investigational
Fluocinolone AcetonideThe bioavailability of Fluocinolone Acetonide can be decreased when combined with Calcium Carbonate.Approved, Investigational, Vet Approved
FluocinonideThe bioavailability of Fluocinonide can be decreased when combined with Calcium Carbonate.Approved, Investigational
FluocortinThe bioavailability of Fluocortin can be decreased when combined with Calcium Carbonate.Experimental
FluocortoloneThe bioavailability of Fluocortolone can be decreased when combined with Calcium Carbonate.Approved, Withdrawn
FluorometholoneThe bioavailability of Fluorometholone can be decreased when combined with Calcium Carbonate.Approved, Investigational
FluperoloneThe bioavailability of Fluperolone can be decreased when combined with Calcium Carbonate.Experimental
FluphenazineCalcium Carbonate can cause a decrease in the absorption of Fluphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FluprednideneThe bioavailability of Fluprednidene can be decreased when combined with Calcium Carbonate.Approved, Withdrawn
FluprednisoloneThe bioavailability of Fluprednisolone can be decreased when combined with Calcium Carbonate.Approved
FlurandrenolideThe bioavailability of Flurandrenolide can be decreased when combined with Calcium Carbonate.Approved
FluspirileneThe therapeutic efficacy of Fluspirilene can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
FluticasoneThe bioavailability of Fluticasone can be decreased when combined with Calcium Carbonate.Approved, Experimental, Investigational
Fluticasone furoateThe bioavailability of Fluticasone furoate can be decreased when combined with Calcium Carbonate.Approved
Fluticasone propionateThe bioavailability of Fluticasone propionate can be decreased when combined with Calcium Carbonate.Approved
FormocortalThe bioavailability of Formocortal can be decreased when combined with Calcium Carbonate.Experimental
FosinoprilCalcium Carbonate can cause a decrease in the absorption of Fosinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FosinoprilatCalcium Carbonate can cause a decrease in the absorption of Fosinoprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
GallopamilThe therapeutic efficacy of Gallopamil can be decreased when used in combination with Calcium Carbonate.Investigational
GarenoxacinCalcium Carbonate can cause a decrease in the absorption of Garenoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
GatifloxacinCalcium Carbonate can cause a decrease in the absorption of Gatifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GefitinibCalcium Carbonate can cause a decrease in the absorption of Gefitinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GemifloxacinCalcium Carbonate can cause a decrease in the absorption of Gemifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
GepefrineCalcium Carbonate may decrease the excretion rate of Gepefrine which could result in a higher serum level.Experimental
Geranyl DiphosphateCalcium Carbonate can cause a decrease in the absorption of Geranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Geranylgeranyl diphosphateCalcium Carbonate can cause a decrease in the absorption of Geranylgeranyl diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
GitoformateCalcium Carbonate may increase the arrhythmogenic and cardiotoxic activities of Gitoformate.Experimental
GleptoferronCalcium Carbonate can cause a decrease in the absorption of Gleptoferron resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
GlycerinThe therapeutic efficacy of Glycerin can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
GrepafloxacinCalcium Carbonate can cause a decrease in the absorption of Grepafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
HalcinonideThe bioavailability of Halcinonide can be decreased when combined with Calcium Carbonate.Approved, Investigational, Withdrawn
HalometasoneThe bioavailability of Halometasone can be decreased when combined with Calcium Carbonate.Experimental
HydrochlorothiazideHydrochlorothiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved, Vet Approved
HydrocortisoneThe bioavailability of Hydrocortisone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
Hydrocortisone aceponateThe bioavailability of Hydrocortisone aceponate can be decreased when combined with Calcium Carbonate.Experimental, Vet Approved
Hydrocortisone acetateThe bioavailability of Hydrocortisone acetate can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
Hydrocortisone butyrateThe bioavailability of Hydrocortisone butyrate can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
Hydrocortisone probutateThe bioavailability of Hydrocortisone probutate can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
Hydrocortisone succinateThe bioavailability of Hydrocortisone succinate can be decreased when combined with Calcium Carbonate.Approved
Hydrocortisone valerateThe bioavailability of Hydrocortisone valerate can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
HydroflumethiazideHydroflumethiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved, Investigational
HydroxyamphetamineCalcium Carbonate may decrease the excretion rate of Hydroxyamphetamine which could result in a higher serum level.Approved
HyoscyamineCalcium Carbonate can cause a decrease in the absorption of Hyoscyamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IbandronateThe serum concentration of Ibandronate can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
ImidaprilCalcium Carbonate can cause a decrease in the absorption of Imidapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Incadronic acidThe serum concentration of Incadronic acid can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
IndapamideIndapamide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
InecalcitolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Inecalcitol.Experimental, Investigational
Iofetamine I-123Calcium Carbonate may decrease the excretion rate of Iofetamine I-123 which could result in a higher serum level.Approved
IronCalcium Carbonate can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranCalcium Carbonate can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron isomaltoside 1000Calcium Carbonate can cause a decrease in the absorption of Iron isomaltoside 1000 resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Iron saccharateCalcium Carbonate can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsradipineThe therapeutic efficacy of Isradipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
ItraconazoleCalcium Carbonate can cause a decrease in the absorption of Itraconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
KetoconazoleCalcium Carbonate can cause a decrease in the absorption of Ketoconazole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LacidipineThe therapeutic efficacy of Lacidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
LactitolThe therapeutic efficacy of Lactitol can be decreased when used in combination with Calcium Carbonate.Investigational
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Calcium Carbonate.Approved
LamotrigineThe therapeutic efficacy of Lamotrigine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Lanatoside CCalcium Carbonate may increase the arrhythmogenic and cardiotoxic activities of Lanatoside C.Experimental
LedipasvirCalcium Carbonate can cause a decrease in the absorption of Ledipasvir resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
LercanidipineThe therapeutic efficacy of Lercanidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
LevetiracetamThe therapeutic efficacy of Levetiracetam can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
LevothyroxineThe therapeutic efficacy of Levothyroxine can be decreased when used in combination with Calcium Carbonate.Approved
LidoflazineThe therapeutic efficacy of Lidoflazine can be decreased when used in combination with Calcium Carbonate.Experimental
LinaclotideThe therapeutic efficacy of Linaclotide can be decreased when used in combination with Calcium Carbonate.Approved
LiothyronineThe therapeutic efficacy of Liothyronine can be decreased when used in combination with Calcium Carbonate.Approved, Vet Approved
LiotrixThe therapeutic efficacy of Liotrix can be decreased when used in combination with Calcium Carbonate.Approved
LisdexamfetamineCalcium Carbonate may decrease the excretion rate of Lisdexamfetamine which could result in a higher serum level.Approved, Investigational
LisinoprilCalcium Carbonate can cause a decrease in the absorption of Lisinopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LomefloxacinCalcium Carbonate can cause a decrease in the absorption of Lomefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
LomerizineThe therapeutic efficacy of Lomerizine can be decreased when used in combination with Calcium Carbonate.Experimental
LoperamideThe therapeutic efficacy of Loperamide can be decreased when used in combination with Calcium Carbonate.Approved
LoteprednolThe bioavailability of Loteprednol can be decreased when combined with Calcium Carbonate.Approved
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
LymecyclineThe serum concentration of Lymecycline can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
Magnesium carbonateThe therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Magnesium citrateThe therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Calcium Carbonate.Approved
Magnesium hydroxideThe therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Magnesium oxideThe therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Calcium Carbonate.Approved
Magnesium peroxideThe therapeutic efficacy of Magnesium peroxide can be decreased when used in combination with Calcium Carbonate.Experimental
ManidipineThe therapeutic efficacy of Manidipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
MannitolThe therapeutic efficacy of Mannitol can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
MaxacalcitolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Maxacalcitol.Approved, Investigational
MecamylamineCalcium Carbonate may decrease the excretion rate of Mecamylamine which could result in a higher serum level.Approved, Investigational
MedrysoneThe bioavailability of Medrysone can be decreased when combined with Calcium Carbonate.Approved
MelengestrolThe bioavailability of Melengestrol can be decreased when combined with Calcium Carbonate.Vet Approved
MemantineCalcium Carbonate may decrease the excretion rate of Memantine which could result in a higher serum level.Approved, Investigational
MentholThe therapeutic efficacy of Menthol can be decreased when used in combination with Calcium Carbonate.Approved
MephedroneCalcium Carbonate may decrease the excretion rate of Mephedrone which could result in a higher serum level.Investigational
MephentermineCalcium Carbonate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MeprednisoneThe bioavailability of Meprednisone can be decreased when combined with Calcium Carbonate.Approved, Investigational
MesalazineCalcium Carbonate can cause a decrease in the absorption of Mesalazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MesoridazineCalcium Carbonate can cause a decrease in the absorption of Mesoridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethacyclineThe serum concentration of Methacycline can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
MethamphetamineCalcium Carbonate may decrease the excretion rate of Methamphetamine which could result in a higher serum level.Approved, Illicit
MethenamineThe therapeutic efficacy of Methenamine can be decreased when used in combination with Calcium Carbonate.Approved, Vet Approved
MethotrimeprazineCalcium Carbonate can cause a decrease in the absorption of Methotrimeprazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethoxyphenamineCalcium Carbonate may decrease the excretion rate of Methoxyphenamine which could result in a higher serum level.Experimental
MethsuximideThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Calcium Carbonate.Approved
MethyclothiazideMethyclothiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Methyl celluloseThe therapeutic efficacy of Methyl cellulose can be decreased when used in combination with Calcium Carbonate.Approved
Methylene blueCalcium Carbonate can cause a decrease in the absorption of Methylene blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
MethylphenidateCalcium Carbonate can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylprednisoloneThe bioavailability of Methylprednisolone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
MetildigoxinCalcium Carbonate may increase the arrhythmogenic and cardiotoxic activities of Metildigoxin.Experimental
MetolazoneMetolazone may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
MibefradilThe therapeutic efficacy of Mibefradil can be decreased when used in combination with Calcium Carbonate.Investigational, Withdrawn
MidomafetamineCalcium Carbonate may decrease the excretion rate of Midomafetamine which could result in a higher serum level.Experimental, Illicit, Investigational
Mineral oilThe therapeutic efficacy of Mineral oil can be decreased when used in combination with Calcium Carbonate.Approved, Vet Approved
MinocyclineThe serum concentration of Minocycline can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
MisoprostolThe serum concentration of Misoprostol can be decreased when it is combined with Calcium Carbonate.Approved
MMDACalcium Carbonate may decrease the excretion rate of MMDA which could result in a higher serum level.Experimental, Illicit
MoexiprilCalcium Carbonate can cause a decrease in the absorption of Moexipril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MometasoneThe bioavailability of Mometasone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
Mometasone furoateThe bioavailability of Mometasone furoate can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
Monopotassium phosphateCalcium Carbonate can cause a decrease in the absorption of Monopotassium phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Vet Approved
MoricizineCalcium Carbonate can cause a decrease in the absorption of Moricizine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
Mycophenolic acidCalcium Carbonate can cause a decrease in the absorption of Mycophenolic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NaftopidilThe therapeutic efficacy of Naftopidil can be decreased when used in combination with Calcium Carbonate.Investigational
Nalidixic AcidCalcium Carbonate can cause a decrease in the absorption of Nalidixic Acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NemonoxacinCalcium Carbonate can cause a decrease in the absorption of Nemonoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
NicardipineThe therapeutic efficacy of Nicardipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
NifedipineThe therapeutic efficacy of Nifedipine can be decreased when used in combination with Calcium Carbonate.Approved
NiguldipineThe therapeutic efficacy of Niguldipine can be decreased when used in combination with Calcium Carbonate.Experimental
NilotinibCalcium Carbonate can cause a decrease in the absorption of Nilotinib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NiludipineThe therapeutic efficacy of Niludipine can be decreased when used in combination with Calcium Carbonate.Experimental
NilvadipineThe therapeutic efficacy of Nilvadipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
NimesulideThe therapeutic efficacy of Nimesulide can be decreased when used in combination with Calcium Carbonate.Approved, Investigational, Withdrawn
NimodipineThe therapeutic efficacy of Nimodipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
NisoldipineThe therapeutic efficacy of Nisoldipine can be decreased when used in combination with Calcium Carbonate.Approved
NitrendipineThe therapeutic efficacy of Nitrendipine can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
NitroprussideCalcium Carbonate can cause a decrease in the absorption of Nitroprusside resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
NorfloxacinCalcium Carbonate can cause a decrease in the absorption of Norfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
NylidrinThe therapeutic efficacy of Nylidrin can be decreased when used in combination with Calcium Carbonate.Approved
OfloxacinCalcium Carbonate can cause a decrease in the absorption of Ofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
OleandrinCalcium Carbonate may increase the arrhythmogenic and cardiotoxic activities of Oleandrin.Experimental, Investigational
OmapatrilatCalcium Carbonate can cause a decrease in the absorption of Omapatrilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
OrbifloxacinCalcium Carbonate can cause a decrease in the absorption of Orbifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Calcium Carbonate.Experimental, Investigational
OuabainCalcium Carbonate may increase the arrhythmogenic and cardiotoxic activities of Ouabain.Approved
OXI-4503Calcium Carbonate can cause a decrease in the absorption of OXI-4503 resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Oxolinic acidCalcium Carbonate can cause a decrease in the absorption of Oxolinic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
OxyphenisatinThe therapeutic efficacy of Oxyphenisatin can be decreased when used in combination with Calcium Carbonate.Investigational, Withdrawn
OxytetracyclineThe serum concentration of Oxytetracycline can be decreased when it is combined with Calcium Carbonate.Approved, Investigational, Vet Approved
PamidronateThe serum concentration of Pamidronate can be decreased when it is combined with Calcium Carbonate.Approved
ParamethasoneThe bioavailability of Paramethasone can be decreased when combined with Calcium Carbonate.Approved
ParicalcitolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Paricalcitol.Approved, Investigational
PazopanibCalcium Carbonate can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PazufloxacinCalcium Carbonate can cause a decrease in the absorption of Pazufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
PefloxacinCalcium Carbonate can cause a decrease in the absorption of Pefloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenfluridolThe therapeutic efficacy of Penfluridol can be decreased when used in combination with Calcium Carbonate.Experimental
PenicillamineCalcium Carbonate can cause a decrease in the absorption of Penicillamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PenimepicyclineThe serum concentration of Penimepicycline can be decreased when it is combined with Calcium Carbonate.Experimental
PentaerithritylThe therapeutic efficacy of Pentaerithrityl can be decreased when used in combination with Calcium Carbonate.Experimental
PerazineCalcium Carbonate can cause a decrease in the absorption of Perazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerflubutaneCalcium Carbonate can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PerindoprilCalcium Carbonate can cause a decrease in the absorption of Perindopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PerindoprilatCalcium Carbonate can cause a decrease in the absorption of Perindoprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PerphenazineCalcium Carbonate can cause a decrease in the absorption of Perphenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PeruvosideCalcium Carbonate may increase the arrhythmogenic and cardiotoxic activities of Peruvoside.Experimental
PhenolphthaleinThe therapeutic efficacy of Phenolphthalein can be decreased when used in combination with Calcium Carbonate.Approved, Withdrawn
PhentermineCalcium Carbonate may decrease the excretion rate of Phentermine which could result in a higher serum level.Approved, Illicit
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Calcium Carbonate.Approved
PinaveriumThe therapeutic efficacy of Pinaverium can be decreased when used in combination with Calcium Carbonate.Approved
Pipemidic acidCalcium Carbonate can cause a decrease in the absorption of Pipemidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
PipotiazineCalcium Carbonate can cause a decrease in the absorption of Pipotiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Piromidic acidCalcium Carbonate can cause a decrease in the absorption of Piromidic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Plantago seedThe therapeutic efficacy of Plantago seed can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
PlecanatideThe therapeutic efficacy of Plecanatide can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
PolycarbophilThe therapeutic efficacy of Polycarbophil can be decreased when used in combination with Calcium Carbonate.Approved
Polyethylene glycolThe therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Calcium Carbonate.Approved, Vet Approved
PolythiazidePolythiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
Potassium acetateThe therapeutic efficacy of Potassium acetate can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
PrednicarbateThe bioavailability of Prednicarbate can be decreased when combined with Calcium Carbonate.Approved, Investigational
PrednisoloneThe bioavailability of Prednisolone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
PrednisoneThe bioavailability of Prednisone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
PrednylideneThe bioavailability of Prednylidene can be decreased when combined with Calcium Carbonate.Experimental
PrenylamineThe therapeutic efficacy of Prenylamine can be decreased when used in combination with Calcium Carbonate.Withdrawn
ProchlorperazineCalcium Carbonate can cause a decrease in the absorption of Prochlorperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromazineCalcium Carbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
PromethazineCalcium Carbonate can cause a decrease in the absorption of Promethazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropericiazineCalcium Carbonate can cause a decrease in the absorption of Propericiazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
PropiopromazineCalcium Carbonate can cause a decrease in the absorption of Propiopromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
ProscillaridinCalcium Carbonate may increase the arrhythmogenic and cardiotoxic activities of Proscillaridin.Experimental
PrucaloprideThe therapeutic efficacy of Prucalopride can be decreased when used in combination with Calcium Carbonate.Approved
PrulifloxacinCalcium Carbonate can cause a decrease in the absorption of Prulifloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Prussian blueCalcium Carbonate can cause a decrease in the absorption of Prussian blue resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
PseudoephedrineCalcium Carbonate may decrease the excretion rate of Pseudoephedrine which could result in a higher serum level.Approved
Pyrophosphoric acidCalcium Carbonate can cause a decrease in the absorption of Pyrophosphoric acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Experimental
QuinaprilCalcium Carbonate can cause a decrease in the absorption of Quinapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
QuinaprilatCalcium Carbonate can cause a decrease in the absorption of Quinaprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
QuinethazoneQuinethazone may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved
QuinidineCalcium Carbonate may decrease the excretion rate of Quinidine which could result in a higher serum level.Approved, Investigational
RamiprilCalcium Carbonate can cause a decrease in the absorption of Ramipril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RamiprilatCalcium Carbonate can cause a decrease in the absorption of Ramiprilat resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
RescinnamineCalcium Carbonate can cause a decrease in the absorption of Rescinnamine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RifampicinCalcium Carbonate can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RimexoloneThe bioavailability of Rimexolone can be decreased when combined with Calcium Carbonate.Approved
RiociguatCalcium Carbonate can cause a decrease in the absorption of Riociguat resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
RitobegronCalcium Carbonate may decrease the excretion rate of Ritobegron which could result in a higher serum level.Investigational
RolitetracyclineThe serum concentration of Rolitetracycline can be decreased when it is combined with Calcium Carbonate.Approved
RosoxacinCalcium Carbonate can cause a decrease in the absorption of Rosoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
RosuvastatinCalcium Carbonate can cause a decrease in the absorption of Rosuvastatin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
RufloxacinCalcium Carbonate can cause a decrease in the absorption of Rufloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
SarafloxacinCalcium Carbonate can cause a decrease in the absorption of Sarafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved, Withdrawn
SeletracetamThe therapeutic efficacy of Seletracetam can be decreased when used in combination with Calcium Carbonate.Investigational
SennosidesThe therapeutic efficacy of Sennosides can be decreased when used in combination with Calcium Carbonate.Approved
SeocalcitolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Seocalcitol.Experimental, Investigational
SitafloxacinCalcium Carbonate can cause a decrease in the absorption of Sitafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
Sodium feredetateCalcium Carbonate can cause a decrease in the absorption of Sodium feredetate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Sodium glycerophosphateCalcium Carbonate can cause a decrease in the absorption of Sodium glycerophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Sodium phosphate, monobasicThe therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Calcium Carbonate.Approved
Sodium sulfateThe therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Calcium Carbonate.Approved, Vet Approved
Sodium tartrateThe therapeutic efficacy of Sodium tartrate can be decreased when used in combination with Calcium Carbonate.Approved
Sodium tripolyphosphateCalcium Carbonate can cause a decrease in the absorption of Sodium tripolyphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Vet Approved
SorbitolThe therapeutic efficacy of Sorbitol can be decreased when used in combination with Calcium Carbonate.Approved
SparfloxacinCalcium Carbonate can cause a decrease in the absorption of Sparfloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
SpiraprilCalcium Carbonate can cause a decrease in the absorption of Spirapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Strontium ranelateThe serum concentration of Strontium ranelate can be decreased when it is combined with Calcium Carbonate.Approved, Withdrawn
SulpirideThe therapeutic efficacy of Sulpiride can be increased when used in combination with Calcium Carbonate.Approved, Investigational
TacalcitolThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Tacalcitol.Experimental, Investigational
Technetium Tc-99m ciprofloxacinCalcium Carbonate can cause a decrease in the absorption of Technetium Tc-99m ciprofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Investigational
Technetium Tc-99m polyphosphateCalcium Carbonate can cause a decrease in the absorption of Technetium Tc-99m polyphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Technetium Tc-99m pyrophosphateCalcium Carbonate can cause a decrease in the absorption of Technetium Tc-99m pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TegaserodThe therapeutic efficacy of Tegaserod can be decreased when used in combination with Calcium Carbonate.Approved, Investigational, Withdrawn
TemafloxacinCalcium Carbonate can cause a decrease in the absorption of Temafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
TemocaprilCalcium Carbonate can cause a decrease in the absorption of Temocapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental, Investigational
TerodilineThe therapeutic efficacy of Terodiline can be decreased when used in combination with Calcium Carbonate.Experimental
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Calcium Carbonate.Approved, Vet Approved
Tetraferric tricitrate decahydrateCalcium Carbonate can cause a decrease in the absorption of Tetraferric tricitrate decahydrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TetrahydropalmatineThe therapeutic efficacy of Tetrahydropalmatine can be decreased when used in combination with Calcium Carbonate.Investigational
TetrandrineThe therapeutic efficacy of Tetrandrine can be decreased when used in combination with Calcium Carbonate.Experimental
ThiazinamCalcium Carbonate can cause a decrease in the absorption of Thiazinam resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThiethylperazineCalcium Carbonate can cause a decrease in the absorption of Thiethylperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
ThioproperazineCalcium Carbonate can cause a decrease in the absorption of Thioproperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ThiopyrophosphateCalcium Carbonate can cause a decrease in the absorption of Thiopyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
ThioridazineCalcium Carbonate can cause a decrease in the absorption of Thioridazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Withdrawn
Thyroid, porcineThe therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Calcium Carbonate.Approved
TigecyclineThe serum concentration of Tigecycline can be decreased when it is combined with Calcium Carbonate.Approved
Tiludronic acidThe serum concentration of Tiludronic acid can be decreased when it is combined with Calcium Carbonate.Approved, Investigational, Vet Approved
TixocortolThe bioavailability of Tixocortol can be decreased when combined with Calcium Carbonate.Approved, Withdrawn
TolevamerThe therapeutic efficacy of Tolevamer can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Tolfenamic AcidThe therapeutic efficacy of Tolfenamic Acid can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
TrandolaprilCalcium Carbonate can cause a decrease in the absorption of Trandolapril resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
TranilastThe therapeutic efficacy of Tranilast can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
TriamcinoloneThe bioavailability of Triamcinolone can be decreased when combined with Calcium Carbonate.Approved, Vet Approved
TrichlormethiazideTrichlormethiazide may decrease the excretion rate of Calcium Carbonate which could result in a higher serum level.Approved, Vet Approved
TriethylenetetramineThe serum concentration of Triethylenetetramine can be decreased when it is combined with Calcium Carbonate.Approved, Investigational
TrifluoperazineCalcium Carbonate can cause a decrease in the absorption of Trifluoperazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
TriflupromazineCalcium Carbonate can cause a decrease in the absorption of Triflupromazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
TrilostaneThe bioavailability of Trilostane can be decreased when combined with Calcium Carbonate.Approved, Investigational, Vet Approved, Withdrawn
TrimebutineThe therapeutic efficacy of Trimebutine can be decreased when used in combination with Calcium Carbonate.Approved
TrimethadioneThe therapeutic efficacy of Trimethadione can be decreased when used in combination with Calcium Carbonate.Approved
TrovafloxacinCalcium Carbonate can cause a decrease in the absorption of Trovafloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational, Withdrawn
UlobetasolThe bioavailability of Ulobetasol can be decreased when combined with Calcium Carbonate.Approved
VerapamilThe therapeutic efficacy of Verapamil can be decreased when used in combination with Calcium Carbonate.Approved
VinpocetineThe therapeutic efficacy of Vinpocetine can be decreased when used in combination with Calcium Carbonate.Investigational
Vitamin DThe risk or severity of adverse effects can be increased when Calcium Carbonate is combined with Vitamin D.Approved, Nutraceutical, Vet Approved
WIN 55212-2The therapeutic efficacy of WIN 55212-2 can be decreased when used in combination with Calcium Carbonate.Experimental
ZiconotideThe therapeutic efficacy of Ziconotide can be decreased when used in combination with Calcium Carbonate.Approved
ZofenoprilCalcium Carbonate can cause a decrease in the absorption of Zofenopril resulting in a reduced serum concentration and potentially a decrease in efficacy.Experimental
Zoledronic acidThe serum concentration of Zoledronic acid can be decreased when it is combined with Calcium Carbonate.Approved
ZonisamideThe therapeutic efficacy of Zonisamide can be decreased when used in combination with Calcium Carbonate.Approved, Investigational
Food Interactions
  • Food increases the absorption of calcium carbonate.

References

Synthesis Reference

Nobuo Someya, Tadao Kitazato, Takao Fujikawa, Yasuo Manabe, "Sintered body of calcium carbonate and process for producing same." U.S. Patent US5187125, issued May, 1940.

US5187125
General References
Not Available
External Links
KEGG Drug
D00932
KEGG Compound
C08129
PubChem Compound
10112
PubChem Substance
310264878
ChemSpider
9708
ChEBI
3311
ChEMBL
CHEMBL1200539
PharmGKB
PA448726
Wikipedia
Calcium_carbonate
ATC Codes
A11GB01 — Ascorbic acid (vit c) and calciumA12AA04 — Calcium carbonateA02AC01 — Calcium carbonate
AHFS Codes
  • 56:04.00 — Antacids and Adsorbents
  • 88:29.00* — Minerals
  • 40:12.00 — Replacement Preparations

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingPreventionMalignant Neoplasm of Colon1
1Active Not RecruitingTreatmentLung Cancer Non-Small Cell Cancer (NSCLC)1
1CompletedBasic ScienceHealthy Volunteers2
1CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentAdvanced Solid Tumors1
1CompletedTreatmentDiabetic Nephropathies1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
1Not Yet RecruitingTreatmentBone Metastases / Sarcoma, Osteogenic1
2CompletedPreventionAflatoxicosis1
2CompletedPreventionDietary Carcinogenesis1
2CompletedTreatmentDiabetic Nephropathies1
2CompletedTreatmentEnd-Stage Renal Disease (ESRD)1
2CompletedTreatmentGaucher's Disease / Osteopenia1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2CompletedTreatmentHyperparathyroidism, Secondary / Renal Osteodystrophy1
2CompletedTreatmentInfection, Human Immunodeficiency Virus I1
2CompletedTreatmentBone destruction / Osteopenia1
2CompletedTreatmentBone destruction / Postmenopausal Osteoporosis (PMO)1
2CompletedTreatmentRheumatoid Arthritis, Juvenile1
2RecruitingTreatmentHyperphosphataemia / Hyperphosphataemia in Chronic Kidney Disease1
2Unknown StatusBasic ScienceMetastatic Colorectal Cancers1
2, 3CompletedPreventionAdenoma benign / Colorectal Cancers / Polyps1
3Active Not RecruitingTreatmentHemodialysis-dependent patients / Hyperphosphataemia1
3CompletedHealth Services ResearchDeficiency, Vitamin D1
3CompletedTreatmentHyperphosphataemia1
3CompletedTreatmentMalignant Lymphomas / Non-Hodgkin's Lymphoma (NHL)1
3Not Yet RecruitingTreatmentLiver Cirrhosis2
3RecruitingTreatmentAging / Pre-Diabetic1
3RecruitingTreatmentLiver Cirrhosis1
3RecruitingTreatmentOsteopenia1
3TerminatedPreventionDiarrhea1
4Active Not RecruitingTreatmentTooth Bleaching / Tooth Sensitivity1
4CompletedTreatmentBMI >27 kg/m2 / BMI >30 kg/m21
4CompletedTreatmentCardiovascular Events / Hemodialysis-dependent patients / Hyperphosphataemia1
4CompletedTreatmentEmergency / Indigestion / Pain1
4CompletedTreatmentNutritional Rickets1
4CompletedTreatmentStage 3 Chronic Kidney Disease1
4Enrolling by InvitationTreatmentBone Diseases, Metabolic / Hyperphosphataemia / Renal Insufficiency,Chronic1
4Not Yet RecruitingTreatmentChronic Hypoparathyroidism1
4RecruitingTreatmentHyperphosphataemia1
4Unknown StatusTreatmentOther Nonspecific Abnormal Serum Enzyme Levels1
Not AvailableActive Not RecruitingSupportive CarePrimary Hyperparathyroidism1
Not AvailableCompletedPreventionChronic Kidney Disease (CKD)1
Not AvailableCompletedTreatmentCardiovascular Mortality1
Not AvailableCompletedTreatmentBone destruction / Cystic Fibrosis (CF)1
Not AvailableCompletedTreatmentEnd Stage Renal Disease (ESRD) / Hemodialysis-dependent patients / Intimal Media Thickness1
Not AvailableCompletedTreatmentImpaired Renal Function1
Not AvailableNot Yet RecruitingTreatmentType 2 Diabetes Mellitus1
Not AvailableRecruitingTreatmentBone destruction / Differentiated Thyroid Cancer (DTC)1
Not AvailableWithdrawnTreatmentChronic Renal Failure (CRF) / End-Stage Renal Disease (ESRD) / Hyperphosphataemia / Insulin Resistance1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Paste, dentifriceOral
Tablet, chewableOral
TabletOral1000 mg/1
TabletOral500 mg/1
TabletOral750 mg/1
Tablet, chewableOral750 1/1
LozengeOral750 mg/1
PasteDental36.4 g/130g
TabletOral
Powder, for solutionOral
Tablet, chewableOral750 mg/1
PowderOral1 g/g
SuspensionOral1250 mg/5mL
TabletOral1250 mg/1
TabletOral648 mg/1
TabletOral1.5 g
WaferOral
TabletOral625 mg
TabletOral1.25 g
Tablet, chewableOral1177 mg/1
Gum, chewingOral500 mg/1
LozengeOral500 mg/1
GranuleOral750 mg/g
KitOral
PowderOral
TabletOral1000 mg
LiquidOral1250 mg/40mL
SolutionOral1250 mg/34mL
Capsule, gelatin coatedOral
SuspensionOral
Tablet, chewableOral420 mg/1
PowderOral1000 mg/1
Tablet, chewableOral350 mg/492mg
Paste, dentifriceDental31.25 g/100g
Tablet, film coatedOral
Bar, chewableOral1177 mg/1
Tablet, chewableOral420 1/1
PasteDental
PasteDental51 g/150g
TabletOral250 mg
Kit
Tablet, coatedOral
PillOral
LiquidTopical
Paste, dentifriceTopical
LiquidOral
Tablet, chewableOral500 mg/1
Tablet, chewableOral648 mg/1
PowderTopical
Paste, dentifriceDental15.85 g/100g
Paste, dentifriceDental
Tablet, chewableOral400 mg/1
TabletOral420 mg
Tablet, chewableOral1000 mg/1
TabletOral420 mg/1
TabletOral500 mg
TabletOral750 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US6814978Yes2002-02-262022-02-26Us
US6165513Yes1998-12-102018-12-10Us
US5994329Yes1999-01-172019-01-17Us
US6015801Yes1999-01-172019-01-17Us
US6432932Yes1999-01-172019-01-17Us
US6465443Yes1999-02-142019-02-14Us
US5989588Yes1998-03-302018-03-30Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility128.0 mg/mLALOGPS
logP0.47ALOGPS
logP0.25ChemAxon
logS-0.08ALOGPS
pKa (Strongest Acidic)6.05ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area63.19 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity31.17 m3·mol-1ChemAxon
Polarizability3.52 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as organic carbonic acids. These are compounds comprising the carbonic acid functional group.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Organic carbonic acids and derivatives
Sub Class
Organic carbonic acids
Direct Parent
Organic carbonic acids
Alternative Parents
Carbonate salts / Organic calcium salts / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Carbonate salt / Carbonic acid / Organic calcium salt / Organic oxygen compound / Organic oxide / Hydrocarbon derivative / Organic salt / Organooxygen compound / Carbonyl group / Aliphatic acyclic compound
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
calcium salt, one-carbon compound, carbonate salt (CHEBI:3311)

Drug created on August 09, 2010 11:35 / Updated on August 14, 2018 04:32